Kyocera (TYO:6971) will transfer its medical business, including artificial joints and dental implants, to Kyocera Medical Corp., a newly established wholly-owned subsidiary, effective October 1, according to its Wednesday bourse filing.
The spin-off, approved by Kyocera's Board on May 28, aims to streamline compliance with stringent global medical regulations and accelerate growth in the specialized medical device sector.
Kyocera Medical will inherit 32.6 billion yen in assets, as of March 2025, and operate independently, with Kyocera retaining full ownership post-split.
The transaction is structured as a simplified absorption-type split, requiring no shareholder approval, and will not impact Kyocera's capital or core operations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.